Simpson Thacher Adds Leading Antitrust and Competition Lawyer Antonio Bavasso
15.12.2020 11:00:00 EET | Business Wire | Press release
Simpson Thacher & Bartlett LLP announced today that Antonio Bavasso will join the Firm’s London office, where he will be a Partner in the Antitrust and Trade Regulation Practice.
Antonio is widely recognized as a leading lawyer in antitrust and regulation, with more than twenty years of experience in some of the most high-profile and precedent-setting merger, behavioural and litigation cases internationally. He advises clients across a broad range of industries, including the technology, media and telecom sectors, in a wide variety of matters before the European Commission, the United Kingdom Competition and Markets Authority and other global competition authorities.
“Antonio has extensive experience that is relevant to our clients, having advised on the antitrust aspects of some of the most high-profile transactions in recent years. That experience will further enhance our ability to provide clients operating across Europe with top-tier advice in both tackling complex transactions and in navigating the enforcement landscape,” said Bill Dougherty, Chairman of Simpson Thacher’s Executive Committee. “We are very pleased to welcome him to the Firm.”
Simpson Thacher’s Antitrust and Trade Regulation Practice advises companies across every major industry on their global antitrust and competition needs, as well as on regulatory issues impacting their interests and operations around the world. The Firm counsels clients on the full array of antitrust enforcement, litigation and investigation issues—from cartel and other anticompetitive activity to litigation of private antitrust actions—as well as regulatory and compliance matters related to cross-border activities such as trade regulation and economic sanctions.
“Antonio is known throughout the market for his superb judgment and ability to provide clients with insightful and practical advice on high-profile, cross-border transactions, as well as in complex antitrust litigation and enforcement matters. This diversity of experience makes him a natural fit for Simpson Thacher and a wonderful addition to both our global M&A and Antitrust and Trade Regulation Practices, and sets the stage for the further expansion of our European antitrust and competition practice,” said David Vann, Head of Antitrust for Europe and Asia at Simpson Thacher.
“Given the sophistication and versatility of his experience, Antonio will deliver tremendous value to our clients and is an excellent addition to our outstanding group of lawyers in London,” added Jason Glover, Managing Partner of the Firm’s London Office. “Along with our recent promotion of Étienne Renaudeau to Partner, we expect David, Antonio and Étienne to spearhead the future growth of our European antitrust practice.”
Antonio joins the Firm from Allen & Overy LLP, where he was Co-Head of the Global Antitrust Practice and Co-Head of the Telecoms, Media and Technology Practice. He is both U.K. and Italy-qualified. He received his J.D., magna cum laude, from the University of Florence and a Ph.D. from University College London, where he is a visiting professor and Co-Founder and Co-Director of the Jevons Institute for Competition Law and Economics. Antonio is also a non-governmental adviser on unilateral practices and merger control for the International Competition Network of competition authorities.
ABOUT SIMPSON THACHER
Simpson Thacher & Bartlett LLP (www.simpsonthacher.com) is one of the world’s leading international law firms. The Firm was established in 1884 and has more than 1,000 lawyers. Headquartered in New York with offices in Beijing, Hong Kong, Houston, London, Los Angeles, Palo Alto, São Paulo, Tokyo and Washington, D.C., the Firm provides coordinated legal advice and transactional capability to clients around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005258/en/
Contact information
Media:
Caroline Fatchett
Simpson Thacher
Assoc. Director, Communications
Caroline.Fatchett@stblaw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom